Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor
Rapid improvement in blood sugar control can temporarily worsen diabetic retinopathy, a diabetes-related eye condition
The effect of food price changes on consumer purchases: a randomised experiment
Stay on your prescribed diet and exercise program while using semaglutide
We are proud to have conducted two well-controlled phase 3 trials in Alzheimers disease that meet the highest standards of research and rigorous methodology, said Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk, in a statement
